Article
A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk.
All News
Article
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Article
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and risk factors.
Laurent ARNAUD
Tweet
✅ Management of #REFRACTORY skin manifestations in patients with #LUPUS ➡️ my practical tips 💪 for #PANLAR2025 🇲🇽 https://t.co/KnJO0eXI4W
Dr. John Cush
Tweet
RHEUMATOLOGISTS: What is your initial steroid dosing regimen w/ Class III/IV Lupus nephritis?
Dr. John Cush
Tweet
RHEUMATOLOGISTS: Which regimen do you choose for Class V Lupus Nephritis
Dr. John Cush
Tweet
Should Lupus Nephritis Receive PJP Prophylaxis?
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and https://t.co/QGHxk3O8q4
Laurent ARNAUD
Tweet
✅ T2T in #Lupus 👀 ⬇️⬇️
📥 LINK https://t.co/F8w8qRZdsS
#NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4
Dr. John Cush
Tweet
Should Lupus Nephritis Receive PJP Prophylaxis?
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and https://t.co/zzRIVG0Sq3
Dr. John Cush
Tweet
2nd Opinions in Rheumatology
https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU
Zahi Touma, MD, PhD
Tweet
43 days to the Lupus Congress 2025 in Toronto 🦋...see you soon!
Abstract Sessions, Poster Tour Presentations, Plenary Sessions, Scientific Sessions, Debate Sessions, Patient Sessions, Fishbowl Discussion, and GALA DINNER on May 23!!!
@LupusCongress https://t.co/MaWjyofnIz
Dr. John Cush
Tweet
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd
Dr. John Cush
Tweet
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/tnYgg6MNXp https://t.co/zJor1oTFfD
Lupus Research
Tweet
📢 Federal funding for lupus research and the Lupus Research Program within the Department of Defense hang in the balance as Congress debates spending priorities.
🔬 Investing in lupus research – and all medical research – is one of the wisest investments we can make. That’s why https://t.co/OgWo5z0fMB
Dr. John Cush
Tweet
Systematic review 21 studies showed potential of RTX with IVIg in autoimmune Dz - 10 studies on pemphigus (85 pts) - all Positive outcomes except 1 paraneoplastic pemphigus. Infections (eg, P. jirovecii pneumonia) seen in 3. 11 studies (24 pts) Rx'd neuropathies, CND lupus& https://t.co/o0RRUBIqmS
Laurent ARNAUD
Tweet
✅ IF YOU ARE LIVING WITH #LUPUS, you can now try #SLAKE, the ONLINE DIGITAL research tool for assessing your ESSENTIAL KNOWLEDGE about #SLE in English, German, Arabic, Spanish, Chinese, Français, Hindi, Indonesian, Dutch, etc... using the following LINK: https://t.co/nSCdBBMEcx https://t.co/PBAPkGynjP
Dr. John Cush
Tweet
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Alberto Giraldo
Tweet
#Thrombocytopenia is common in #antiphospholipid syndrome (APS), and is likely associated with more severe disease. Although the pathophysiology underlying thrombocytopenia in APS has yet to be definitively revealed, mechanisms that play a role (at least in subsets of patients) https://t.co/pUXmb1irbw
Dr. John Cush
Tweet
Full read Overview of the effects of Menopause and Estrogen on autoimmune disorders https://t.co/NpVPrnPT6x https://t.co/wt9f5D7WXL
Dr. John Cush
Tweet
Post hoc analysis of 5 ph III Belimumab RCTs (BLISS, etc, N=3086) on skin outcomes BILAG & SLEDAI-2K), BEL was superior to PBO (mcBILAG OR: 1.29; mcSLEDAI-2K OR: 1.37). Also if SLEDAI ≥10 & dsDNA+ pts. BEL prevented skin flares (HR 0.70) https://t.co/p1MVVf97Go https://t.co/qwWUyegpyi
